Microencapsulated cells genetically modified to overexpress human transforming growth factor-β1: Viability and functionality in allogeneic and xenogeneic implant models

Tissue Engineering

Volumn 12, Issue 7, 2006, Pages 1733-1739

  Paek, Hyun J ^a,c   Campaner, Anelisa B ^a   Kim, Jennifer L ^a   Golden, Louis ^a   Aaron, Roy K ^b   Ciombor, Deborah M ^b   Morgan, Jeffrey R ^a   Lysaght, Michael J ^a  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c Tissue Genesis Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARTILAGE; ENCAPSULATION; GROWTH KINETICS; IMPLANTS (SURGICAL); ORTHOPEDICS;

ALLOGENEIC MODELS; ENCAPSULATED CELLS; FIBROBLASTS; MICROCAPSULES;

TISSUE CULTURE;

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CALCIUM ALGINATE; GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARTILAGE; CELL SURVIVAL; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; EXPLANT; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROCAPSULE; MICROENCAPSULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REGENERATION; TISSUE ENGINEERING; WILD TYPE; XENOTRANSPLANTATION;

ALGINATES; ANIMALS; BIOPROSTHESIS; CAPSULES; CELL SURVIVAL; FIBROBLASTS; GENE EXPRESSION; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; MICE; NIH 3T3 CELLS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE ENGINEERING; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

MURINAE;

EID: 33746706895     PISSN: 10763279     EISSN: None     Source Type: Journal    
DOI: 10.1089/ten.2006.12.1733     Document Type: Article

References (20)

1. Bell, E., Ehrlich, H.P., Buttle, D.J., and Nakatsuji, T. Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. Science 211, 1052, 1981.
2. Bell, E., Sher, S., Hull, B., Merrill, C., Rosen, S., Chamson, A., Asselineau, D., Dubertret, L., Coulomb, B., Lapiere, C., Nusgens, B., and Neveux, Y. The reconstitution of living skin. J. Invest. Dermatol. 81, 2s, 1983.
3. Toledo-Pereyra, L.H., Bandlien, K.O., Gordon, D.A., MacKenzie, G.H., and Reyman, T.A. Renal subcapsular islet cell transplantation. Diabetes 33, 910, 1984.
4. Michalewicz, P., Laurito, C.E., Pappas, G.D., Lu, Y., and Yeomans, D.C. Purification of adrenal chromaffin cell increases antinociceptive efficacy of xenotransplants without immunosuppression. Cell Transplant. 8, 103, 1999.
5. Brittberg, M., Lindahl, A., Nilsson, A., Ohlsson, C., Isaksson, O., and Peterson, L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N. Engl. J. Med. 331, 889, 1994.
6. Tan, W., and Desai, T.A. Layer-by-layer microfluidics for biomimetic three-dimensional structures. Biomaterials 25, 1355, 2004.
7. Gudjonsson, T., Ronnov-Jessen, L., Villadsen, R., Bissell, M.J., and Petersen, O.W. To create the correct microenvironment: three-dimensional heterotypic collagen assays for human breast epithelial morphogenesis and neoplasia. Methods 30, 247, 2003.
8. Pei, M., Aaron, R.K., and Ciombor, D.M. Engineered cartilage from synovium-a developmental approach. Trans. Orthop. Res. Soc. 29, 720, 2004.
9. Pei, M., Aaron, R.K., and Ciombor, D.M. Modulation of chondrogenesis in synovial fibroblast engineered cartilage by sequential growth factors. Trans. Orthop. Res. Soc. 30, 136, 2005.
10. Pei, M., Aaron, R.K., and Ciombor, D.M. TGF-β1-dependent chondrogenic effect of IGF-1 and FGF-2 on synovial fibroblasts. Trans. Orthop. Res. Soc. 30, 1452, 2005.
11. Lu, L., Yaszemski, M.J., and Mikos, A.G. TGF-beta1 release from biodegradable polymer microparticles: its effects on marrow stromal osteoblast function. J. Bone Joint Surg. 83A, S82, 2001.
12. Mann, B.K., Schmedlen, R.H., and West, J.L. Tethered-TGF-beta increases extracellular matrix production of vascular smooth muscle cells. Biomaterials 22, 439, 2001.
13. Neidert, M.R., Lee, E.S., Oegema, T.R., and Tranquille, R.T. Enhanced fibrin remodeling in vitro with TGF-beta1, insulin and plasmin for improved tissue-equivalents. Biomaterials 23, 3717, 2002.
14. Walsh, S., Jefferiss, C., Stewart, K., and Beresford, J.N. TGFbeta1 limits the expansion of the osteoprogenitor fraction in culture of human bone marrow stromal cells. Cell Tissue Res. 311, 187, 2003.
15. 2+-alginate microcapsules. ASAIO J. 51, 379, 2005.
16. Campaner, A.B., Ferreira, L.M., Fillo, A.G., Bruder, J.M., Cusick, J., and Morgan, J.R. Upregulation of TGF-β1 expression may be necessary but is not sufficient for excessive scarring. J. Invest. Dermatol. 126, 1168, 2006.
17. Nimni, M.E. Polypeptide growth factors: targeted delivery systems. Biomaterials 18, 1201, 1997.
18. Gleizes, P., Munger, J.S., Nunes, I., Harpel, J.G., Mazzieri, R., Noguera, I., and Rifkin, D.B. TGF-β latency: biological significance and mechanisms of activation. Stem Cells 15, 190, 1997.
19. Khalil, N. TGF-β: from latent to active. Microbes Infect. 1, 1255, 1999.
20. Rahman, N.A. Development and characterization of double walled microspheres from poly(L-lactide) and poly(D,L-lactide-co-glycolide) blends. Brown University, 2003.